Page 40 - 2019_02-Haematologica-web

A. Varthaman et al. Blood. 2003;101(4):1351-1358.
64. James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self- peptide. J Thromb Haemost. 2007;5(12): 2399-2407.
65. Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P. Haemophilia. 2010;16 (102):44-55.
66. James EA, van Haren SD, Ettinger RA, et al. T-cell responses in two unrelated hemophil- ia A inhibitor subjects include an epitope at the factor VIII R593C missense site. J Thromb Haemost. 2011;9(4):689-699.
67. Pashov AD, Calvez T, Gilardin L, et al. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. Haemophilia. 2013;20(2):176-184.
68. Hemophilia.org. https://http://www.hemo- philia.org/Researchers-Healthcare- Providers/Medical-and-Scientific-Advisory- Council-MASAC/MASAC-Recom- mendations/MASAC-Recommendation-
On-SIPPET-Survey-of-Inhibitors-in-Plasma-
Product-Exposed-Toddlers.
69. Peyvandi F, Mannucci PM, Garagiola I, et al.
A randomized trial of factor VIII and neutral- izing antibodies in hemophilia A. N Engl J Med. 2016;374(21):2054-2064.
70. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreat- ed patients with hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4648- 4654.
71. Hay CR, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors through- out life in severe hemophilia A in the United Kingdom. Blood. 2011;117(23): 6367-6370.
72. Jagger A, Shimojima Y, Goronzy JJ, Weyand CM. Regulatory T cells and the immune aging process: a mini-review. Gerontology. 2014;60(2):130-137.
73. Pautard B, D'Oiron R, Li Thiao Te V, et al. Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells. J Thromb Haemost. 2011;9(6):1163- 1170.
74. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after
desensitization in patients with hemophilia
A. J Clin Invest. 1996;97(6):1382-1388.
75. Dimitrov JD, Roumenina LT, Plantier JL, et al. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope. J Thromb Haemost.
2010.
76. Matino D, Gargaro M, Santagostino E, et al.
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest. 2015;125(10):3766-3781.
77. Moghimi B, Sack BK, Nayak S, Markusic DM, Mah CS, Herzog RW. Induction of tol- erance to factor VIII by transient co-admin- istration with rapamycin. J Thromb Haemost. 2011;9(8):1524-1533.
78. Hassan S, Fijnvandraat K, van der Bom JG, Gouw SC. Preventing or eradicating factor VIII antibody formation in patients with hemophilia A: what can we learn from other disorders? Semin Thromb Hemost. 2018;44 (6):531-543.
79. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822.
80. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9): 809-818.
244
haematologica | 2019; 104(2)